참고문헌 (27)

1. McIntosh, Christopher H.S., Demuth, Hans-Ulrich, Pospisilik, J.Andrew, Pederson, Raymond. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?. Regulatory peptides, vol.128, no.2, 159-165.

   상세보기

2. Weber, A. E.. Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes. Journal of medicinal chemistry, vol.47, no.17, 4135-4141.

   상세보기

3. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug discovery today, vol.10, no.10, 703-710.

   상세보기

4. Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., Marsilio, F., McCann, M. E., Patel, R. A., Petrov, A., Scapin, G., Patel, S. B., Roy, R. S., Wu, J. K., Wyvratt, M. J., Zhang, B. B., Zhu, L., Thornberry, N. A., Weber, A. E.. (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. Journal of medicinal chemistry, vol.48, no.1, 141-151.

   상세보기

5. Curr Opin Investig Drugs Deacon CF 419 6 2005 

   상세보기

6. Creutzfeldt, Werner. The [pre-] history of the incretin concept. Regulatory peptides, vol.128, no.2, 87-91.

   상세보기

7. Vilsbøll, Tina, Krarup, Thure, Deacon, Carolyn F., Madsbad, Sten, Holst, Jens J.. Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients. Diabetes, vol.50, no.3, 609-613.

   상세보기

8. Ahrén, Bo, Holst, Jens J, Mårtensson, Hans, Balkan, Börk. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. European journal of pharmacology, vol.404, no.1, 239-245.

   상세보기

9. Pederson, Raymond A, White, Heather A, Schlenzig, Dagmar, Pauly, Robert P, McIntosh, Christopher H S, Demuth, Hans-Ulrich. Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide. Diabetes, vol.47, no.8, 1253-1258.

   상세보기

10. Marguet, Didier, Baggio, Laurie, Kobayashi, Takashi, Bernard, Anne-Marie, Pierres, Michel, Nielsen, Per F., Ribel, Ulla, Watanabe, Takeshi, Drucker, Daniel J., Wagtmann, Nicolai. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proceedings of the National Academy of Sciences of the United States of America, vol.97, no.12, 6874-6879.

    상세보기

11. Diabetes Bergman A 2100 54 1 2005 

12. Diabetes Herman G 497-P 54 1 2005 

13. Diabetes Bergman A 2101-PO 54 1 2005 

14. Mitani, Hironobu, Takimoto, Misato, Hughes, Thomas E., Kimura, Masaaki. Dipeptidyl Peptidase IV Inhibition Improves Impaired Glucose Tolerance in High-Fat Diet-Fed Rats: Study Using a Fischer 344 Rat Substrain Deficient in Its Enzyme Activity. The Japanese journal of pharmacology : official publication of the Japanese Pharmacological Society, vol.88, no.4, 442-450.

    상세보기

15. Conarello, Stacey L., Li, Zhihua, Ronan, John, Roy, Ranabir Sinha, Zhu, Lan, Jiang, Guoqiang, Liu, Franklin, Woods, John, Zycband, Emanuel, Moller, David E., Thornberry, Nancy A., Zhang, Bei B.. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, vol.100, no.11, 6825-6830.

    상세보기

16. Diabetologia Herman GA A287 1 2004 

17. Diabetes Herman G A134 54 1 2005 

18. Diabetes Scott R A10 54 1 2005 

19. Diabetes Brazg R A3 54 1 2005 

20. Diabetes Herman G A505 54 1 2005 

21. Mest, H.-J., Mentlein, R.. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia, vol.48, no.4, 616-620.

    상세보기

22. Mentlein, Rolf. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regulatory peptides, vol.85, no.1, 9-24.

    상세보기

23. Deacon, Carolyn F, Ahrén, Bo, Holst, Jens J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. Expert opinion on investigational drugs, vol.13, no.9, 1091-1102.

    상세보기

24. 10.1210/jc.2003-031907 

    

25. Ahrén, Bo, Gomis, Ramon, Standl, Eberhard, Mills, David, Schweizer, Anja. Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes. Diabetes care, vol.27, no.12, 2874-2880.

    상세보기

26. Pospisilik, J.A., Stafford, S.G., Demuth, H-U., Brownsey, R., Parkhouse, W., Finegood, D.T., McIntosh, C.H.S., Pederson, R.A.. Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and β-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats. Diabetes, vol.51, no.4, 943-950.

    상세보기

27. Herman, G.A., Stevens, C., Van Dyck, K., Bergman, A., Yi, B., De Smet, M., Snyder, K., Hilliard, D., Tanen, M., Tanaka, W., Wang, A.Q., Zeng, W., Musson, D., Winchell, G., Davies, M.J., Ramael, S., Gottesdiener, K.M., Wagner, J.A.. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical pharmacology and therapeutics, vol.78, no.6, 675-688.

    상세보기